---
schema_version: "secwatch.filing_event.v1"
accession: "0001658247-26-000039"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:50:25.624550+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Crinetics Q1 2026: PALSONIFY net revenue $10.3M; EU approval; net loss $127.8M

## Summary
- PALSONIFY net product revenue $10.3M in Q1 2026, up from $5.4M in Q4 2025; 232 enrollment forms received.
- European Commission approved PALSONIFY for acromegaly in April 2026; MAA submitted to Brazil, NDA in Japan.
- Net loss $127.8M vs $96.8M in Q1 2025; cash $1.3B after $380M equity offering.
- Initiated BALANCE-CAH Phase 2/3 trial; on track to start Phase 2/3 trial for atumelnant in Cushing's in Q2 2026.
- 2026 GAAP operating expense guidance $600M-$650M; non-GAAP $480M-$520M.

## SEC filing metadata
- accession: 0001658247-26-000039
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000039/0001658247-26-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000039/crnx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001658247-26-000039
- JSON: https://secwatch.observer/filing/0001658247-26-000039.json
- Plain text: https://secwatch.observer/filing/0001658247-26-000039.txt

## Source-grounded claims
- claim_id: 3e40faf429c77e627c4e0fa9cc2c53c53cc3959a
  claim: Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2026 results: revenue $10.7 million. Guidance reaffirmed.
  evidence_excerpt: ACTH antagonist, atumelnant, in a broad population including patients with both Cushing’s disease and ectopic ACTH syndrome. First Quarter 2026 Financial Results: • Revenue was $10.7 million for the quarter ended March 31, 2026, compared to $0.4 million for the same period in 2025. Revenue for the quarter ended March 31, 2026 includes $10.3 million in net product
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000039/0001658247-26-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.